CompletedInterventionalPhase 3Last updated Mar 24, 2015

A Study to Determine if 0.6% ISV-403 is Safe and Effective in the Treatment of Bacterial Conjunctivitis.

A Study to Evaluate the Clinical and Microbial Efficacy of 0.6% ISV-403 Compared to Vehicle in the Treatment of Bacterial Conjunctivitis.

Overview

ClinicalTrials.gov ID: NCT00347932
Lead Sponsor: Bausch & Lomb IncorporatedINDUSTRY
Brief Summary: Evaluation of the clinical and microbial efficacy of 0.6% ISV-403, compared to vehicle in the treatment of bacterial conjunctivitis.
Study Type: Interventional

Status

Study Record Dates

NCT00622908Completed

Clinical and Microbial Efficacy of ISV403 in Bacterial Conjunctivitis

NCT00348348Completed

A Study to Investigate the Safety and Efficacy of BOL-303224 in the Treatment of Bacterial Conjunctivitis

NCT01740388Terminated

Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial Conjunctivitis

NCT00972777Completed

Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis

NCT01175590Completed

Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle

NCT01120418Completed

Corneal Endothelial Cell Density Changes In Healthy Subjects, When Administered ISV-403 for 5 Days